Where Global Innovation
and Capital Meet
Sectors Consumer University Energy Financial Healthcare Industrial IT Media Services Telecoms Transport The Art of CVC Startups

Page 266

Allscripts carries out $100m Practice Fusion acquisition

Qualcomm-backed Practice Fusion has agreed to an acquisition by Allscripts, having once been touted for an IPO that would have valued it at $1.5bn.

Jan 9, 2018

BrightFunnel reaches its Terminus in acquisition deal

Terminus has bought BrightFunnel, a marketing analytics platform that had raised $9.5m from backers including Salesforce Ventures and Bloomberg Beta.

Jan 5, 2018

Editorial: Insights into the transport revolution

As China-based ride-hailing service Didi Chuxing's acqures a majority of Brazil-based peer 99, below is a version of a speech presented in a keynote at the Corporate Venture in Brasil conference in October 2017.

Jan 5, 2018

Microsoft advances to Avere acquisition

Western Digital and Google-backed data storage platform Avere Systems has agreed to be acquired by Microsoft, having raised $97m in funding.

Jan 4, 2018

Didi Chuxing digs out $600m for 99

The on-demand ride provider reportedly now owns a 90% share of its Brazilian counterpart, whose investors also included Qualcomm and SoftBank.

Jan 4, 2018

Restorbio readies $85m initial public offering

Restorbio, an aging-related disease drug developer co-founded by PureTech Health, also counts Novartis as a shareholder.

Jan 3, 2018

Armo arcs to IPO stage

GV and Celgene-backed Armo BioSciences has filed to raise up to $86.3m in an offering that will fund clinical tests for its lead immuno-oncology candidate.

Jan 3, 2018

Apple brings Buddybuild into the group

Corporate venturing unit Bloomberg Beta has exited app testing platform developer BuddyBuild through an acquisition of undisclosed size by Apple.

Jan 3, 2018

Menlo Therapeutics eases way to IPO

The Novo and Merck-backed pruritus therapy developer has filed to raise up to $97.8m, having already secured almost $110m in VC funding.

Jan 3, 2018

Solid Bio to sound out public markets

Biogen-backed Duchenne muscular dystrophy (DMD) treatment developer Solid Biosciences has filed to raise up to $100m.

Jan 3, 2018

© 2024 Mawsonia Ltd. All rights reserved.
test reg

Login

Not yet subscribed?

See your subscription offers here